AQST R&D to Revenue

Aquestive Therapeutics Inc · R&D to Revenue

AQST logo

AQST R&D to Revenue

Latest reported38.59%
AQST FY R&D/Revenue (29.83% → 38.59%)
High-resolution chart · PNG

AQST r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Aquestive Therapeutics Inc R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
38.5947%
35.2322%
25.9059%
36.6632%
33.536%
43.3728%
39.1074%
34.2755%
33.0748%
29.8349%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.